|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
|
30481041 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CYP1B1 is related to tumor formation and is over-expressed in a variety of cancer cells.
|
31493422 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours.
|
29332599 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The GEP analysis showed that the down-regulated genes in tumor tissue were CYP3A4 in 56 patients (61%), CYP2C8 in 44 patients (48%), CYP2C19 in 30 patients (33%), CYP2D6 in 11 patients (12%), CYP3A5 in 7 patients (8%) and CYP1B1 in 2 patients (2%).
|
29774122 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our review of the current literature suggests a positive loop between inflammatory cytokines and CYP1B1, which in turn may play a key role in cancer angiogenesis, acting on both cancer cells and the tumor microenvironment.
|
29197745 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work is the first attempt to visualize CYP1B1 for noninvasive imaging of tumor which could provide new approach for tumor diagnosis.
|
30422652 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified two polymorphisms in CYP1B1 and ABCC2 associated with tumor pathological response following docetaxel or doxorubicin neoadjuvant monotherapy, respectively.
|
30334909 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of CYP1B1 shRNA attenuated growth of pre-existing tumors.
|
28388569 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The influence of CXCR4 on tumor cell chemoresistance, apoptosis and growth, as well as the relationship between CXCR4 and the expression of cytochrome p450 associated molecule CYP1B1 in NSCLC were evaluated.
|
27922681 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ASMT:CYP1B1 index negatively correlated with tumor grade, as well as with the expression of pro-proliferation and anti-apoptotic NFκB target genes.
|
26510398 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, CYP1B1 expression was associated with tumor grade and stage.
|
26626260 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, these results have implications concerning the contribution of inflammatory factors to carcinogenesis, since enhanced CYP1B1 induction during inflammation may alter metabolism of exogenous carcinogens, as well as endogenous CYP1B1 substrates playing role in tumor development.
|
25233930 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with GSTT1 deletion had tumors of more advanced stages, and those with Val432 polymorphism in CYP1B1 had tumors of higher Fuhrman grade.
|
21458313 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, incubation of tumor microsomal protein in 4 bladder and 3 colon samples with a CYP1B1 specific antibody revealed a large reduction (72.5 ± 5.5 % for bladder and 71.8 ± 7.2% for colon) in catalytic activity, indicating that the activity was mainly attributed to CYP1B1 expression.
|
24358191 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To identify molecular targets for combination treatment, we conducted cDNA microarray analysis and found three genes encoding enzyme [matrix metalloproteinase-7 (MMP-7), transmembrane protease serin 4 (TMPRSS4) and cytocrome P450 1B1 (CYP1B1)] to be upregulated in SKOV/ip-FuEP2/Ex2-derived tumors.
|
23708855 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytochrome P450 1B1 (CYP1B1) is a key P450 enzyme involved in the metabolism of exogenous and endogenous substrates in endocrine-mediated tumors such as prostate cancer.
|
22327650 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The high CYP1B1/CYP1A1 and low COMT/CYP1B1 expression ratios detected in ERα(+) tumors suggested an accumulation of 4-hydroxyestradiol metabolite under high body estrogen, whereas comparable CYP1A1 and CYP1B1 expression plus estrogen-inducible COMT expression might favor the formation of 2-methoxyestradiol in ERα(-) tumors.
|
21920623 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In particular, we validated tumor-associated hypermethylation in the cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1B1 (CYP1B1) promoters of bladder cancer tissues by bisulfite sequence analysis and methylation-specific PCR and also by in vitro treatment of T-24 bladder cancer cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine.
|
21990318 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYP1B1 was found to be downregulated in 77.78% (28/36) tumor tissues in comparison to their corresponding normal tissues as well as in the epithelial dysplasia lesion compared to its matched normal tissue at the transcriptional level, and in 92.86% (26/28) of tumor tissues at the protein level.
|
22114726 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytology brush samples from 12 tobacco and betel related OSCC and 17 nonmalignant oral lesions revealed B2M mRNA was enriched in tumor samples while CYP1B1 mRNA was reduced, similar to what was seen in the model system.
|
21549635 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed phase I and phase II XME activities as well as the expression of the CYP isoforms CYP1A1 and CYP1B1, oxidative stress markers, and the expression of NFkappaB family members in tumor and adjacent tissues by immunohistochemical localization and Western blot analyses.
|
19995559 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the genes analyzed, those most often targeted by amplification were SDC1 and CYP1B1 in 2p21 approximately p25 and CDK6 and MET in 7q21 approximately q31, but all of the 15 genes tested were found to be amplified in at least two tumors.
|
18262049 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYP1B1 expression was on average 50-fold higher than that of CYP2E1 with overexpression detected in one third of the tumors.
|
18214058 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated AhR and CYP1B1 but not CYP1A1 before tumor formation in a rat model of mammary tumorigenesis suggested differential CYP1B1 regulation by a constitutively active AhR.
|
18059014 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm.
|
18347981 |
2008 |